Petition to add Belzutifan to the PBS for patients with Von Hippel Lindau disease

Von Hippel Lindau disease (VHL) causes devastating predisposition to a range of tumours, and is currently managed with surgery or radiotherapy. Belzutifan, a proven effective medication available in the US and parts of the UK, but is not accessible in Australia through the PBS, despite TGA approval and orphan drug classification. It is cost prohibitive for the majority of patients at around $12,000 per month out of pocket. The below petition is being organised by Neuroendocrine Cancer Australia and we invite you to sign the petition to assist in advocating for the medication to be added to the PBS.

https://aph.gov.au/e-petitions/petition/EN6026